• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Probi

Less than 1K followers
All
Webcasts
Press releases
3rd party
ShowingAll content types

Press release22.07.2025 klo 16.00

Women's Health by Probi wins NutraIngredients-USA Award for Innovation in Women's Health

Probi
Press release28.05.2025 klo 09.37

Probi Female wins prestigious NutraIngredients Award 2025 for innovation in women's health

Probi
Press release07.05.2025 klo 03.30

First-of-its-kind: Nomura Dairy and Probi[ ]introduce probiotic-enhanced carrot juice to Japan

Probi

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release03.02.2025 klo 10.20

Delisting of Probi

Probi
Regulatory press release20.01.2025 klo 23.01

Notice of Extraordinary General Meeting in Probi AB (publ)

Probi
Regulatory press release20.01.2025 klo 23.00

Probi applies for delisting and convenes an Extraordinary General Meeting

Probi
Regulatory press release09.01.2025 klo 09.00

Probi postpones year-end report 2024

Probi
Regulatory press release13.12.2024 klo 18.17

Statement from the independent bid committee of Probi in relation to the public takeover offer by Symrise

Probi
Regulatory press release20.11.2024 klo 08.19

Probi's Board comments on Symrise's public takeover offer

Probi
Regulatory press release13.11.2024 klo 12.00

Probi CFO departure

Probi
Press release23.10.2024 klo 14.00

Probi Launches Clinically-Supported Probiotic Solution for Metabolic Health at SupplySide West 2024

Probi
Third party research23.10.2024 klo 08.24

Probi: Managing costs well in Q3 - ABG

Miss on Q3 sales (-12%) and EBITDA (-10%) vs ABGSCe China faced headwinds due to macroeconomic factors EBITDA revised down by 2-3% for '24e-'26e Encouraging B2C sales efforts in the Nordics Probi reported a soft Q3'24 with sales amounting to SEK 143....

Probi
Probi, Audiocast with teleconference, Q3'24
Webcast22.10.2024 klo 11.00

Probi, Audiocast with teleconference, Q3'24

Probi
Regulatory press release22.10.2024 klo 09.00

Probi: Q3 2024: Tangible improvement in operations

Probi
Press release17.10.2024 klo 09.50

Presentation of Probi's Q3 Report 2024

Probi
Press release16.10.2024 klo 14.30

Probi partners with Global BHP BrainTrust and the FINGERS Brain Health Institute to counteract dementia

Probi
Press release10.10.2024 klo 10.00

Nordic launch of Probi Sense - a unique dietary supplement for the mental capacity

Probi
Press release24.09.2024 klo 14.00

New study strengthens Probi[ ][®]s L. plantarum HEAL9[®] strain in cognitive function

Probi
Third party research17.07.2024 klo 09.29

Probi: FY'24e marks a transition to a promising future - ABG

- Beat on Q2 sales (+3%) and EBITDA (+24%) vs ABGSCe - EBITDA up 2% for '24e and 1% for '25e - Our comprehensive analysis indicates a promising long-term outlook Americas and EMEA progressed well in Q2 Probi reported a strong Q2'24 driven by growth in...

Probi
Probi, Audiocast with teleconference, Q2'24
Webcast16.07.2024 klo 11.00

Probi, Audiocast with teleconference, Q2'24

Probi